Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Hexaxim vs Infanrix Hexa in Thai Infants
NCT00401531Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2006
- Primary completion
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi. Primary endpoint: Number of Participants Achieving Seroprotection Against Hepatitis B and Haemophilus Influenzae Type b. Started Oct 2006; status: completed.
02
Drugs
hexaxim
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT00401531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401531.